DEP-1 Antibody (B-2): sc-390404

DEP-1 Antibody (B-2) is a mouse monoclonal IgM antibody that detects DEP-1 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). DEP-1 (B-2) antibody is available in a non-conjugated form, allowing for versatile experimental use. Density-enhanced phosphatase-1 (DEP-1), also known as HPTP-eta/CD148, plays a crucial role in signal transduction within leukocytes and is integral to cellular differentiation processes. DEP-1 features an extracellular segment with eight fibronectin type III repeats, a single transmembrane segment, and a unique intracellular protein tyrosine phosphatase domain. This structural configuration enables DEP-1 to interact effectively with various signaling pathways, influencing the activation and differentiation of immune cells. In lymphoid organs, DEP-1 is prominently expressed on B and T cells, granulocytes, macrophages, certain dendritic cells, mature thymocytes, and neutrophils, while in non-lymphoid tissues, DEP-1 appears in fibrocytes, melanocytes, Schwann cells, and various epithelial cell types with glandular or endocrine functions. Notably, in Jurkat T cells, DEP-1 inhibits T cell receptor-mediated activation, leading to decreased expression of early activation markers such as CD69, reduced tyrosine phosphorylation of key intracellular proteins including the tyrosine kinase ZAP-70, and impaired activation of mitogen-activated protein kinases. Despite intrinsic enzymatic activity, DEP-1 can paradoxically induce protein tyrosine phosphorylation in human lymphocytes and serine/threonine or tyrosine phosphorylation in certain tumor cell lines, highlighting DEP-1′s complex regulatory role in cellular signaling.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

DEP-1 Antibody (B-2) References:

1. DEP-1 protein tyrosine phosphatase inhibits proliferation and migration of colon carcinoma cells and is upregulated by protective nutrients.  |  Balavenkatraman, KK., et al. 2006. Oncogene. 25: 6319-24. PMID: 16682945
2. Tumor suppressor density-enhanced phosphatase-1 (DEP-1) inhibits the RAS pathway by direct dephosphorylation of ERK1/2 kinases.  |  Sacco, F., et al. 2009. J Biol Chem. 284: 22048-22058. PMID: 19494114
3. Protein-tyrosine phosphatase DEP-1 controls receptor tyrosine kinase FLT3 signaling.  |  Arora, D., et al. 2011. J Biol Chem. 286: 10918-29. PMID: 21262971
4. Targeting density-enhanced phosphatase-1 (DEP-1) with antisense oligonucleotides improves the metabolic phenotype in high-fat diet-fed mice.  |  Krüger, J., et al. 2013. Cell Commun Signal. 11: 49. PMID: 23889985
5. The protein tyrosine phosphatase DEP-1/PTPRJ promotes breast cancer cell invasion and metastasis.  |  Spring, K., et al. 2015. Oncogene. 34: 5536-47. PMID: 25772245
6. Enhanced insulin signaling in density-enhanced phosphatase-1 (DEP-1) knockout mice.  |  Krüger, J., et al. 2015. Mol Metab. 4: 325-36. PMID: 25830095
7. Tyrosine Phosphatase PTPRJ/DEP-1 Is an Essential Promoter of Vascular Permeability, Angiogenesis, and Tumor Progression.  |  Fournier, P., et al. 2016. Cancer Res. 76: 5080-91. PMID: 27364551
8. The protein tyrosine phosphatase PTPRJ/DEP-1 contributes to the regulation of the Notch-signaling pathway and sprouting angiogenesis.  |  Fournier, P., et al. 2020. Angiogenesis. 23: 145-157. PMID: 31598898
9. Loss of PTPRJ/DEP-1 enhances NF2/Merlin-dependent meningioma development.  |  Waldt, N., et al. 2020. J Neurol Sci. 408: 116553. PMID: 31715329
10. DEP-1 is a brain insulin receptor phosphatase that prevents the simultaneous activation of counteracting metabolic pathways.  |  Chopra, S., et al. 2024. Cell Rep. 43: 114984. PMID: 39589923

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-DEP-1 Antibody (B-2) has 0 citations in a variety of scientific publications.

Primary antibodies like Anti-DEP-1 Antibody (B-2) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

DEP-1 Antibody (B-2) Specifications

Alternate Product Name: DEP-1

Product Clone Name: B-2

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgM kappa light chain

Amino Acids: 31-65

Epitope Target: DEP-1

Epitope Species: rat

Product Reactivity/Detection: DEP-1

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, ELISA

Vialing Information: Each vial contains 200 µg IgM kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 0 citations in various scientific publications

Available Conjugates/Forms for DEP-1 Antibody (B-2): P: Blocking Peptide

The preferred DEP-1 antibody is DEP-1 Antibody (143-41): sc-21761.